Evaxion Biotech A/S (NASDAQ:EVAX) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research note issued to investors on Friday morning, Benzinga reports. HC Wainwright currently has a $14.00 price objective on the stock.

Evaxion Biotech A/S Trading Down 3.0 %

Shares of EVAX traded down $0.08 during mid-day trading on Friday, reaching $2.59. The company had a trading volume of 11,698 shares, compared to its average volume of 229,773. Evaxion Biotech A/S has a fifty-two week low of $2.26 and a fifty-two week high of $13.61. The firm has a fifty day simple moving average of $2.96 and a 200-day simple moving average of $3.20. The stock has a market cap of $14.45 million, a price-to-earnings ratio of -1.10 and a beta of -0.26. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.08. The firm had revenue of $3.02 million during the quarter, compared to analyst estimates of $0.19 million. On average, sell-side analysts anticipate that Evaxion Biotech A/S will post -0.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Armistice Capital LLC lifted its holdings in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 392,000 shares of the company’s stock after acquiring an additional 25,000 shares during the quarter. Armistice Capital LLC owned about 7.24% of Evaxion Biotech A/S worth $1,137,000 as of its most recent filing with the Securities and Exchange Commission. 11.04% of the stock is owned by hedge funds and other institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.